SCHEMBL4092707

SCHEMBL4092707

CCN(CC)C(=O)COC(=O)CCc1cc(S(C)(=O)=O)cc(-c2nc(=O)c3ccc(Cl)cc3s2)n1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 1/20 0.33
PTGS2 P35354 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
THRB P10828 1/20 0.31
GAA P10253 1/20 0.31
NPC1 O15118 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4085450 0.92 KDM4E (0.36) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL4087175 0.88 CASP3 (0.34) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL4082720 0.88 HTT (0.39) MAPTMEN1KMT2AKDM4ECASP3
SCHEMBL4082600 0.86 EGFR (0.38) MAPTMEN1KMT2AKDM4EPTGS2
SCHEMBL13940269 0.86 MCL1 (0.31) MAPTKDM4ECASP3SENP8SENP7
SCHEMBL4094700 0.84 POLB (0.33) KDM4ECASP3SENP8SENP7SENP6
SCHEMBL4082987 0.84 CYP3A4 (0.31) KDM4EALDH1A1HPGDHSD17B10PTGS2
SCHEMBL4094643 0.84 HDAC6 (0.42) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL4622103 0.82 LMNA (0.35) MAPTMEN1KMT2AKDM4EHPGD
SCHEMBL4093006 0.82 MEN1 (0.33) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-29 US disclosed
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF MIF, CCL2, MSR1 MAPT 4755/4885MEN1 2393/4885KMT2A 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.